Welcome to our dedicated page for AEONWS news (Ticker: AEONWS), a resource for investors and traders seeking the latest updates and insights on AEONWS stock.
AEON Biopharma, Inc. (NYSE: AEON, AEON WS) is a clinical-stage biopharmaceutical company specializing in the development of its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, for treating a range of debilitating medical conditions. With a primary focus on the neurosciences market, AEON is dedicated to advancing therapeutic solutions that significantly improve patient outcomes.
AEON has recently completed a Phase 2 study of ABP-450 for the treatment of cervical dystonia and is currently conducting another Phase 2 study aimed at the preventative treatment of both chronic and episodic migraine. Notably, ABP-450 is the same botulinum toxin complex that is already approved and marketed for cosmetic purposes under the brand name Jeuveau by Evolus. The manufacturing of ABP-450 is carried out by Daewoong, adhering to current Good Manufacturing Practices (cGMP) in a facility approved by the U.S. Food and Drug Administration (FDA), Health Canada, and the European Medicines Agency (EMA).
As part of its ongoing efforts, AEON has recently secured a notice of allowance from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application No. 17/006,685, titled “Neurotoxin Compositions for Use in Treating Headache.” This soon-to-be-issued patent provides protection in the U.S. for the claimed methods of using ABP-450 to treat migraine, extending until 2041. This patent aligns with AEON’s business strategy to exclusively utilize botulinum toxins for therapeutic indications, enhancing the safety and tolerability of its treatment protocols.
The company has a strategic partnership with Strathspey Crown Holdings Group, LLC, a growth equity firm specializing in healthcare, technology, and fintech. Strathspey Crown recently clarified its holdings of AEON class A common stock, reflecting the transfer of 7,380,394 AEON shares to its limited partners. These shares remain subject to transfer restrictions under securities laws and a 12-month lockup period expiring on July 21, 2024, as stipulated in AEON's bylaws.
AEON boasts an experienced management team with extensive expertise in biopharmaceuticals and botulinum toxin development. The company holds exclusive development and distribution rights for ABP-450 in the U.S., Canada, the European Union, the United Kingdom, and other international territories. This strong leadership and strategic positioning underscore AEON's commitment to pioneering treatments in the neurosciences sector.
For more information about AEON and its innovative therapeutic neurotoxin development, visit www.aeonbiopharma.com.
FAQ
What does AEON Biopharma specialize in?
What is ABP-450?
What recent achievements has AEON Biopharma made?
Who manufactures ABP-450?
What are the exclusive territories where AEON holds development and distribution rights for ABP-450?
What is the significance of the recent patent allowance for AEON?
Who is Strathspey Crown Holdings Group, LLC?
What recent transaction did Strathspey Crown Holdings Group, LLC undertake involving AEON shares?
What is AEON’s approach to intellectual property protection?
Where can I find more information about AEON Biopharma?
